Glucagon-like peptide-1 receptor agonists (GLP-1RAs), specifically exenatide, were initially approved by the Food and Drug Administration (FDA) in 2005 for type 2 diabetes mellitus (T2D).1 Over the past 2 decades, GLP-1RA use has grown exponentially for both T2D and obesity, and numerous studies have shown improvement in cardiovascular and kidney outcomes.2–8. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.